Stockreport

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria [Yahoo! Financ...

Mineralys Therapeutics, Inc.  (MLYS) 
PDF Mineralys Therapeutics, Inc. Tue, February 4, 2025 at 2:00 PM GMT+1 6 min read In This Article MLYS Mineralys Therapeutics, Inc. Continues to anticipate ann [Read more]